The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...
In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...
Zacks Investment Research on MSN
SENS Eversense 365 integrated with twiist gains full availability
Senseonics SENS recently announced the full availability of its long-term, implantable Continuous Glucose Monitoring (CGM) ...
Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results